Subscribe to our Newsletter

From Joe Burnett, President & CEO:

The first few months of 2021 have been exciting for the ClearPoint team. First, we announced two impactful partnerships: one with global health technology leader Philips to license and commercialize the ClearPoint Maestro™ Brain Model with applications across drug delivery, DBS and LiTT, as well as with Utah-based Blackrock MicroSystems to co-develop its Microelectric Recording platform for use both in the MRI suite and Operating Room. Second, we supported our partner PTC Therapeutics for the first early access gene therapy cases in France to treat the rare pediatric genetic disorder AADC Deficiency. Third, we installed our first system in Denmark where we deployed our 2.0 software version for the first time in Europe. And finally, we expanded our Biologics and Drug Delivery team to better serve the translational needs of our gene and stem cell partners and drive consistent results from bench to bedside.

Our goal throughout the last 12 months was to exit the COVID-19 pandemic in a better position than we started. Despite still dealing with COVID-related case postponements, we believe our strategy, pipeline of partners, and portfolio are more resilient than ever. Last month we led a significant capital raise for the company to ensure we have a strong balance sheet to weather future storms that come our way. Adding this new funding will also allow our talented team to relentlessly execute on our strategy and help speed the introduction of new innovations to neurosurgeons and their patients in the United States, Europe and beyond.

We are grateful to our loyal customers, partners and teammates after a year that has taken such a large toll on families and businesses around the globe. We look forward to continuing to partner with you to drive neurosurgical innovation, whether it be in the pre-clinical setting, the MRI suite, or the OR. If you have any questions about the company or our strategy, please reach out to me personally.